TwoBostonteaching hospitals are stepping up research into cardiovascular disease in separate programs that illustrate the deepening collaboration between academic medical centers and the biopharmaceutical industry.

TuftsMedicalCenterhas received a $1.7 million federal stimulus award from the National Institutes of Health, one of Tufts’ largest grants of the year, to explore cell-penetrating peptide treatments for heart disease, using a technology licensed to Ascent Therapeutics of Cambridge. The project will employ a half-dozen researchers at Tufts’ labs inChinatownand at outside partners and contractors.

Brigham and Women’s Hospital, meanwhile, will open the Center for Interdisciplinary Cardiovascular Sciences in a partnership with Japanese drug maker Kowa Company Ltd. to conduct basic research into the genesis of diseases such as atherosclerosis and diabetes. The Kowa-funded center, which will be the largest of theBostonhospital’s global pharmaceutical collaborations, will employ about 12 researchers in the Longwood Medical Area.

“This is a perfect example of an industry and academic medical relationship working together toward a goal of speeding the development of new treatments,’’ said Masanori Aikawa, assistant professor of medicine at Brigham and Women’s and Harvard Medical School, who will direct the center. Research projects are set to begin next month at the center, located on the 17th floor of the Center for Life Sciences,

.

The programs are part of an effort by state life sciences researchers and the Patrick administration to strengthen alliances between hospitals and biopharmaceutical companies, said Susan R. Windham-Bannister, chief executive of theMassachusettsLifeSciencesCenterinWaltham, which has spent $3.7 million this year on cooperative research grants funding six other collaborations.

“Massachusettsis the global leader in taking promising technologies and translating them into advance stages of development,’’ Windham-Bannister said, noting that the state is the top per-capita recipient of NIH research grants. “The academic medical centers are playing a critical role in developing young technologies. It is no longer cost-effective for companies to do all the research internally.’’

Athan Kuliopulos, principal investigator for the new NIH grant at Tufts, is an assistant professor of medicine and biochemistry and director of the school’s Hemostasis and Thrombosis Laboratory. In 2007, he and Tufts colleague Lidija Covic cofounded Ascent, which licensed from Tufts technology on which Kuliopulos and Covic had been working for the past decade. The technology involves a class of molecules known as Pepducins, which can treat acute cardiovascular stress and inhibit blood-clotting arterial thrombosis.